What Falling Estimates & Price Mean for Patterson Companies (PDCO) Fri, 24 Nov 2017 14:00:02 +0000 It seems to be a wise decision for investors to drop Patterson Companies (PDCO) stock considering its negative estimate revision, price depreciation as well as unfavorable Zacks rank.
AmerisourceBergen to Take Over H. D. Smith for $815 Million Wed, 22 Nov 2017 14:14:02 +0000 AmerisourceBergen (ABC) strives to strengthen core businesses. The H. D. Smith buyout is likely to strengthen the Pharmaceutical Distribution Segment.
Orthofix products address health needs of patients with internal and external fixators, nailing and plating systems, soft tissue management products, bone growth stimulators, bracing and pain management products
Orthofix to Present at 29th Annual Piper Jaffray Healthcare Conference Tue, 21 Nov 2017 13:30:00 +0000 Orthofix International N.V. , a diversified, global medical device company, today announced that President and Chief Executive Officer Brad Mason will present at the 29th Annual Piper Jaffray Healthcare Conference in New York, NY on Wednesday, November 29, 2017 at 10:10 a.m.
ETFs with exposure to Orthofix International NV : November 15, 2017 Wed, 15 Nov 2017 17:13:24 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Orthofix International NV Here are 5 ETFs with the largest exposure to OFIX-US. Comparing the performance and risk of Orthofix International NV with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Orthofix to Present at Jefferies 2017 London Healthcare Conference Mon, 06 Nov 2017 13:00:00 +0000 Orthofix International N.V. , a diversified, global medical device company, today announced that President and Chief Executive Officer Brad Mason will present at the Jefferies 2017 London Healthcare Conference in London, on Thursday, November 16, 2017 at 10:20 a.m.
Orthofix International NV :OFIX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017 Wed, 01 Nov 2017 13:41:56 +0000 Categories: Yahoo FinanceGet free summary analysis Orthofix International NV reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Orthofix International NV – NuVasive, Inc. and Stryker Corporation (NUVA-US and SYK-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 105.25 million, Net ... Read more
(Read more...)
Orthofix beats 3Q profit forecasts Mon, 30 Oct 2017 20:11:19 +0000 The Willemstad, Netherlands Antilles-based company said it had profit of 19 cents per share. Earnings, adjusted for one-time gains and costs, came to 42 cents per share. The results surpassed Wall Street ...
Orthofix International Reports Third Quarter 2017 Financial Results Mon, 30 Oct 2017 20:02:00 +0000 Orthofix International N.V. today reported its financial results for the third quarter ended September 30, 2017. Net sales were $105.2 million, diluted earnings per share from continuing operations was $0.18 and adjusted earnings per share from continuing operations was $0.42.
Orthofix Wins 2017 Spine Technology Award for STIM onTrack Mobile App Wed, 25 Oct 2017 12:00:00 +0000 Orthofix International N.V. , a diversified, global medical device company, today announced that its STIM onTrack™ mobile app has earned the 2017 Spine Technology Award in the Cervical Care category from Orthopedics This Week, the most widely read publication in the Orthopedics industry.
Fresenius Medical (FMS) Well Poised on Growth Strategy 2020 Tue, 10 Oct 2017 13:00:01 +0000 Fresenius Medical (FMS) is banking on its Growth Strategy 2020 plan for gaining market traction in the future. However, lackluster performance in the bourse is a concern.
Boston Scientific Grows on New Products, Currency Woe Ails Mon, 09 Oct 2017 18:59:06 +0000 Boston Scientific (BSX) is gaining traction on product launch and accretive acquisitions. Yet an unfavorable currency movement is a major dampener.
See what the IHS Markit Score report has to say about Intuitive Surgical Inc. Mon, 20 Nov 2017 13:07:08 +0000 The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ISRG totaled $679 million.
Trump Focuses on APAC: 4 MedTech Stocks to Watch Thu, 16 Nov 2017 17:30:05 +0000 Considering Trump's growing focus on APAC, the region seems to be poised to yield accretive returns over the long term. Favorable MedTech trends in APAC hold promise.
IRadimed posts 3Q profit Mon, 30 Oct 2017 11:19:46 +0000 On a per-share basis, the Winter Springs, Florida-based company said it had net income of 2 cents. Earnings, adjusted for stock option expense, came to 7 cents per share. The maker of IV devices that can ...
iRadimed Corp to Host Earnings Call Mon, 30 Oct 2017 11:10:00 +0000 NEW YORK, NY / ACCESSWIRE / October 30, 2017 / iRadimed Corp (NASDAQ: IRMD ) will be discussing their earnings results in their Q3 Earnings Call to be held on October 30, 2017 at 11:00 AM Eastern Time. ...
IRADIMED CORPORATION Announces Third Quarter 2017 Financial Results Mon, 30 Oct 2017 11:00:00 +0000 Reports third quarter 2017 revenue of $5.7 million Reports third quarter 2017 GAAP diluted EPS of $0.02 and non-GAAP diluted EPS of $0.07 Increases full year 2017 non-GAAP diluted EPS guidance. WINTER ...
ETFs with exposure to IRadimed Corp. : October 27, 2017 Fri, 27 Oct 2017 15:00:47 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to IRadimed Corp. Here are 5 ETFs with the largest exposure to IRMD-US. Comparing the performance and risk of IRadimed Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
(Read more...)
IRadimed Corp.: Price momentum supported by strong fundamentals Fri, 27 Oct 2017 14:28:22 +0000 Categories: Yahoo FinanceIRadimed Corp. relative valuation is NEUTRAL and it has a fundamental analysis score of 81. Our analysis is based on comparing IRadimed Corp. with the following peers – AtriCure, Inc., Milestone Scientific Inc., Cooper Companies, Inc. and DexCom, Inc. (ATRC-US, MLSS-US, COO-US and DXCM-US). IRadimed Corp. has shown good performance overall, both over the last ... Read more
(Read more...)
ETFs with exposure to IRadimed Corp. : September 26, 2017 Tue, 26 Sep 2017 14:55:02 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to IRadimed Corp. Here are 5 ETFs with the largest exposure to IRMD-US. Comparing the performance and risk of IRadimed Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
(Read more...)
IRadimed Corp. :IRMD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 25, 2017 Mon, 25 Sep 2017 12:52:17 +0000 Categories: Yahoo FinanceGet free summary analysis IRadimed Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of IRadimed Corp. – AtriCure, Inc., Milestone Scientific Inc., Cooper Companies, Inc. and DexCom, Inc. (ATRC-US, MLSS-US, COO-US and DXCM-US) that have also reported for this period. Highlights Summary numbers: ... Read more
(Read more...)
AxoGen Announces Closing of Public Offering of Common Stock Mon, 20 Nov 2017 16:15:00 +0000 ALACHUA, Fla., Nov. 20, 2017-- AxoGen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve damage, today announced the closing of its previously announced ...
AxoGen, Inc. (Nasdaq: AXGN) to Ring The Nasdaq Stock Market Opening Bell Mon, 20 Nov 2017 15:00:00 +0000 What: AxoGen, a global leader in innovative surgical solutions for peripheral nerve regeneration and repair, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Karen Zaderej, President, ...
AxoGen Advances its Platform for Nerve Repair at Annual Analyst and Investor Day Mon, 20 Nov 2017 13:00:00 +0000 Company Announces Expanded Application to Address Breast Reconstruction Neurotization Following Mastectomy. Company Will Continue Developing its Portfolio of Products Toward Future Applications Including ...
ETFs with exposure to AxoGen, Inc. : November 16, 2017 Thu, 16 Nov 2017 16:12:47 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AxoGen, Inc. Here are 5 ETFs with the largest exposure to AXGN-US. Comparing the performance and risk of AxoGen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
(Read more...)
November Growth Stocks To Look Out For Thu, 16 Nov 2017 16:02:30 +0000 Individual investors like stocks with a high growth potential. These companies have a strong outlook that can bring a significant upside to your portfolio, regardless of market cyclicality. If yourRead More...
AxoGen, Inc. Announces Pricing of Public Offering of Common Stock Thu, 16 Nov 2017 13:40:18 +0000 ALACHUA, Fla., Nov. 16, 2017-- AxoGen, Inc., a global leader in developing and marketing innovative surgical solutions for the repair of peripheral nerve damage, announced today that it has priced an underwritten ...
AxoGen, Inc. Announces Proposed Public Offering of Common Stock Wed, 15 Nov 2017 21:43:24 +0000 ALACHUA, Fla., Nov. 15, 2017-- AxoGen, Inc., a global leader in developing and marketing innovative surgical solutions for the repair of peripheral nerve damage, announced today that it has commenced an ...
AxoGen, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference Tue, 14 Nov 2017 12:00:00 +0000 ALACHUA, Fla., Nov. 14, 2017-- AxoGen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, President and Chief ...
AxoGen, Inc. :AXGN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017 Fri, 03 Nov 2017 14:03:37 +0000 Categories: Yahoo FinanceGet free summary analysis AxoGen, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of AxoGen, Inc. – Thermo Fisher Scientific Inc. and Boston Scientific Corporation (TMO-US and BSX-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 16.05 million, ... Read more
(Read more...)
ViewRay advanced radiation therapy technology for the treatment of cancer
Earnings Review and Free Research Report: Natus Medical’s Revenue Soared 34.9% Wed, 22 Nov 2017 12:40:00 +0000 Research Desk Line-up: ViewRay Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 22, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Natus Medical Inc. (NASDAQ: BABY ...
ViewRay® to Participate in Upcoming Conferences Tue, 21 Nov 2017 21:01:00 +0000 CLEVELAND , Nov. 21, 2017 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that Chris Raanes , Chief Executive Officer, and Ajay Bansal , Chief Financial Officer are scheduled to participate ...
VRAY: Financial Results For Third Quarter 2017. Revising Revenue Guidance Mon, 20 Nov 2017 20:00:00 +0000 On November 13, 2017 VRAY (VRAY) announced third quarter financial results. The firm recorded revenue of little over $12 million for the quarter. Management had originally guided for total sales of 7-8 systems for 2H 2017. We had accordingly estimated revenues of $16.8 million and $30.8 million for Q3 and Q4 of 2017 respectively resulting in an estimate of $47.6 million for 2H 2017. However, the company recorded sales of only two systems during Q3, resulting in lower than anticipated revenue for the quarter. The firm modestly revised their revenue guidance to be between $42 and $47 million for 2017. Based on this revised guidance, we model five installations of the MRIdian systems for the fourth quarter.
ViewRay reports 3Q loss Mon, 13 Nov 2017 12:13:21 +0000 The Oakwood Village, Ohio-based company said it had a loss of 19 cents per share. The radiation therapy systems maker posted revenue of $12.2 million in the period. ViewRay expects full-year revenue in ...
ViewRay Reports Third Quarter 2017 Financial Results Mon, 13 Nov 2017 12:00:00 +0000 Strong Order Momentum in Q3, continuing in Q4 CLEVELAND , Nov. 13, 2017 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the third quarter and nine months ended September ...
ViewRay, Inc. to Host Earnings Call Mon, 13 Nov 2017 11:10:00 +0000 \NEW YORK, NY / ACCESSWIRE / November 13, 2017 / ViewRay, Inc. (NASDAQ: VRAY ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 13, 2017 at 8:30 AM Eastern ...
Washington University Completes Installation of Second MRIdian MR-Guided Radiotherapy System from ViewRay Fri, 10 Nov 2017 22:33:00 +0000 CLEVELAND, Nov. 10, 2017 /PRNewswire/ -- ViewRay, Inc. (VRAY) announced today that the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri, has completed installation of their new MRIdian Linac. This marks the hospital's second MRIdian system, furthering their leadership role in the delivery of MR-guided radiation therapy. With a focus on improving patient care and outcomes, Siteman Cancer Center has a rich history of utilizing the most advanced medical technologies available.
CUTERA is a global provider of Face + Body laser, light, and energy-based aesthetic systems. The Company designs, develops, manufactures, and markets its platforms for use by physicians and other qualified practitioners. Headquartered in California, Cutera has international offices in Australia, Belgium, Canada, France, Hong Kong, Japan, and Switzerland. In addition, the Company distributes its products globally through distributors in over 65 countries.
Cutera Reports Third Quarter 2017 Financial Results Tue, 07 Nov 2017 21:05:00 +0000 Cutera, Inc. , a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, today reported financial results for the third quarter and nine months ended September 30, ...
Cutera, Inc. to Host Earnings Call Tue, 07 Nov 2017 15:10:00 +0000 NEW YORK, NY / ACCESSWIRE / November 7, 2017 / Cutera, Inc. (NASDAQ: CUTR ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 7, 2017 at 4:30 PM Eastern Time. To ...
ETFs with exposure to Cutera, Inc. : November 7, 2017 Tue, 07 Nov 2017 15:05:07 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cutera, Inc. Here are 5 ETFs with the largest exposure to CUTR-US. Comparing the performance and risk of Cutera, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
(Read more...)
Cutera, Inc. breached its 50 day moving average in a Bullish Manner : CUTR-US : November 6, 2017 Mon, 06 Nov 2017 12:15:58 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Cutera, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more
(Read more...)
Cutera, Inc. Names Elisha Wade Finney to its Board of Directors Wed, 01 Nov 2017 11:30:00 +0000 BRISBANE, Calif., Nov. 01, 2017-- Cutera, Inc., a leading provider of laser and energy-based aesthetic systems for practitioners worldwide, announced that Elisha Wade Finney has been appointed to its board ...
Cutera, Inc. – Value Analysis (NASDAQ:CUTR) : October 23, 2017 Mon, 23 Oct 2017 15:32:20 +0000 Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Cutera, Inc. a score of 75. Our analysis is based on comparing Cutera, Inc. with the following peers – PhotoMedex, Inc., Misonix, Inc., IRIDEX Corporation and Dynatronics Corporation (PHMD-US, MSON-US, IRIX-US and DYNT-US). Investment Outlook Cutera, Inc. has a fundamental score of 75 and has a relative ... Read more
(Read more...)
Cutera, Inc. breached its 50 day moving average in a Bearish Manner : CUTR-US : October 20, 2017 Fri, 20 Oct 2017 12:27:13 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Cutera, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more
(Read more...)
Cutera to Present at Two Upcoming Healthcare Conferences Fri, 20 Oct 2017 11:30:00 +0000 BRISBANE, Calif., Oct. 20, 2017-- Cutera, Inc., a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, announced today that James Reinstein, Chief Executive Officer, ...
Exactech, Inc. to Host Earnings Call Tue, 31 Oct 2017 11:55:00 +0000 NEW YORK, NY / ACCESSWIRE / October 31, 2017 / Exactech, Inc. (NASDAQ: EXAC ) will be discussing their earnings results in their Q3 Earnings Call to be held on October 31, 2017 at 10:00 AM Eastern Time. ...
Exactech posts 3Q profit Mon, 30 Oct 2017 20:43:43 +0000 On a per-share basis, the Gainsville, Florida-based company said it had net income of 20 cents. The maker of bone and joint restoration products posted revenue of $61.4 million in the period. Exactech ...
Exactech Q3 Revenue $61.4 Million Mon, 30 Oct 2017 20:05:00 +0000 Exactech, Inc. , a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, announced today that revenue for the third quarter of 2017 increased 2% to $61.4 million from $59.9 million in the third quarter of 2016, and 2% on a constant currency basis.
Exactech Inc (EXAC): What Does The Future Look Like? Mon, 30 Oct 2017 13:01:33 +0000 Exactech Inc (NASDAQ:EXAC)’s predicted earnings growth next year is expected to be a gigantic one, coming in over 150%. With the recent EPS being $0.055, expected growth will push theRead More...
Leading manufacturer of wheelchairs, respiratory products and other home health care and mobility products for people with disabilities. Browse our home medical equipment catalog.
Invacare Corp. :IVC-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017 Tue, 21 Nov 2017 13:29:06 +0000 Categories: Yahoo FinanceGet free summary analysis Invacare Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Invacare Corp. – Hill-Rom Holdings, Inc., Stryker Corporation, Inogen, Inc., STERIS Plc, Teleflex Incorporated, Sonoma Pharmaceuticals, Inc. and Owens & Minor, Inc. (HRC-US, SYK-US, INGN-US, STE-US, TFX-US, SNOA-US and ... Read more
(Read more...)
Invacare Declares Quarterly Dividend Thu, 16 Nov 2017 15:40:00 +0000 The Board of Directors of Invacare Corporation announced that it declared a cash dividend of $.0125 per share on its common shares and $.011364 per share on its Class B common shares payable January 16, 2018 to shareholders of record on January 4, 2018.
Invacare Corp. breached its 50 day moving average in a Bullish Manner : IVC-US : November 9, 2017 Thu, 09 Nov 2017 12:21:02 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Invacare Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more
(Read more...)
Invacare Corporation to Host Earnings Call Wed, 08 Nov 2017 11:20:00 +0000 NEW YORK, NY / ACCESSWIRE / November 8, 2017 / Invacare Corporation (NYSE: IVC ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 8:30 AM Eastern Time. ...
Invacare reports 3Q loss Wed, 08 Nov 2017 00:40:51 +0000 The Elyria, Ohio-based company said it had a loss of 57 cents per share. Losses, adjusted for non-recurring costs, came to 41 cents per share. The wheelchair, crutches and motorized scooter company posted ...
See what the IHS Markit Score report has to say about ResMed Inc. Mon, 20 Nov 2017 13:08:07 +0000 Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on October 31. Index (PMI) data, output in the Healthcare sector is rising.
3 Top Medical Device Stocks to Buy Now Sat, 18 Nov 2017 16:32:00 +0000 Looking to put money to work in this under-the-radar sector? Here are three top stocks to consider.
ETFs with exposure to ResMed, Inc. : November 13, 2017 Mon, 13 Nov 2017 18:07:13 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ResMed, Inc. Here are 5 ETFs with the largest exposure to RMD-US. Comparing the performance and risk of ResMed, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
(Read more...)
Statement by ResMed on United Kingdom Case with Fisher & Paykel Mon, 13 Nov 2017 01:51:00 +0000 SAN DIEGO , Nov. 13, 2017 /PRNewswire/ -- ResMed (NYSE: RMD, ASX: RMD) today issued the following statement from David Pendarvis , the company's global general counsel and chief administrative officer: ...
Fisher & Paykel says UK court rules rival Resmed's patent is invalid Sun, 12 Nov 2017 22:16:16 +0000 New Zealand's Fisher & Paykel Healthcare (FPH.NZ) said on Monday that it could continue to sell its sleep apnea masks in Britain as a UK court had ruled that rival Resmed Inc's (RMD.N) patent was invalid. Fisher & Paykel filed the case against California-based Resmed in Britain's High Court in 2016, and has similar legal proceedings underway in Germany, after Resmed had said the New Zealand company's masks violated Resmed patents. "This result confirms that UK patients can continue to purchase and enjoy the benefits of our high-performance masks," Fisher & Paykel said in a statement in which it announced the UK court ruling.
SleepScore Labs Launches the World's Most Advanced Sleep Improvement System Fri, 10 Nov 2017 14:00:00 +0000 CARLSBAD, Calif., Nov. 10, 2017 /PRNewswire/ -- SleepScore Labs, the company behind the most advanced non-contact sleep improvement systems for consumers, announced today the availability of its newest non-contact device, SleepScore Max. SleepScore Max, available for purchase at www.sleepscore.com, is the world's most accurate and sophisticated sleep improvement system. Small and attractive enough to sit on a nightstand, the device calculates a nightly SleepScore (between 0–100) based on an individual's quality and quantity of sleep – without the need for a wearable tracker or bed strip beneath the mattress.
Read This Before Buying ResMed Inc (RMD) For Its Upcoming $0.35 Dividend Sat, 04 Nov 2017 00:49:27 +0000 Important news for shareholders and potential investors in ResMed Inc (NYSE:RMD): The dividend payment of $0.35 per share will be distributed into shareholder on 14 December 2017, and the stockRead More...
ResMed, Inc. :RMD-US: Earnings Analysis: Q1, 2018 By the Numbers : November 1, 2017 Wed, 01 Nov 2017 13:34:16 +0000 Categories: Yahoo FinanceGet free summary analysis ResMed, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of ResMed, Inc. – Thermo Fisher Scientific Inc. (TMO-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 523.66 million, Net Earnings of USD 86.13 million. ... Read more
(Read more...)
Globus Medical is the worlds largest privately held Spine Company. Globus has many spinal devices for spinal surgery and focuses on minimally invasive surgery.
See what the IHS Markit Score report has to say about Globus Medical Inc. Wed, 22 Nov 2017 13:03:08 +0000 Short interest is moderate for GMED with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, ETFs holding GMED are favorable, with net inflows of $4.14 billion.
Globus Medical (GMED) Looks Good: Stock Adds 7.5% in Session Fri, 10 Nov 2017 13:36:01 +0000 Globus Medical (GMED) saw its shares rise nearly 8% on the day after the company reported year-over-year growth in third-quarter earnings and revenues.
Globus Medical meets 3Q profit forecasts Wed, 08 Nov 2017 21:47:35 +0000 On a per-share basis, the Audubon, Pennsylvania-based company said it had profit of 26 cents. Earnings, adjusted for one-time gains and costs, came to 30 cents per share. The results met Wall Street expectations. ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.
Accum/Dist: 1.96 (median winner: 1.53)
Instit. Ownership: 85% (median winner: 63%)
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.